Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
Different factors limit early- and late-season windows of opportunity for monarch development.
Yang LH, Swan K, Bastin E, Aguilar J, Cenzer M, Codd A, Gonzalez N, Hayes T, Higgins A, Lor X, Macharaga C, McMunn M, Oto K, Winarto N, Wong D, Yang T, Afridi N, Aguilar S, Allison A, Ambrose-Winters A, Amescua E, Apse M, Avoce N, Bastin K, Bolander E, Burroughs J, Cabrera C, Candy M, Cavett A, Cavett M, Chang L, Claret M, Coleman D, Concha J, Danzer P, DaRosa J, Dufresne A, Duisenberg C, Earl A, Eckey E, English M, Espejo A, Faith E, Fang A, Gamez A, Garcini J, Garcini J, Gilbert-Igelsrud G, Goedde-Matthews K, Grahn S, Guerra P, Guerra V, Hagedorn M, Hall K, Hall G, Hammond J, Hargadon C, Henley V, Hinesley S, Jacobs C, Johnson C, Johnson T, Johnson Z, Juchau E, Kaplan C, Katznelson A, Keeley R, Kubik T, Lam T, Lansing C, Lara A, Le V, Lee B, Lee K, Lemmo M, Lucio S, Luo A, Malakzay S, Mangney L, Martin J, Matern W, McConnell B, McHale M, McIsaac G, McLennan C, Milbrodt S, Mohammed M, Mooney-McCarthy M, Morgan L, Mullin C, Needles S, Nunes K, O'Keeffe F, O'Keeffe O, Osgood G, Padilla J, Padilla S, Palacio I, Panelli V, Paulson K, Pearson J, Perez T, Phrakonekham B, Pitsillides I, Preisler A, Preisler N, Ramirez H, Ransom S, Renaud C, Rocha T, Saris H, Schemrich R, Schoenig… See abstract for full author list ➔ Yang LH, et al. Among authors: panelli v. Ecol Evol. 2022 Jul 11;12(7):e9039. doi: 10.1002/ece3.9039. eCollection 2022 Jul. Ecol Evol. 2022. PMID: 35845370 Free PMC article.